



Attorney Docket: Surr.113

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: ALLISON

SERIAL NO.: 10/632,694

FILED: AUGUST 1, 2003

TITLE: MODIFIED ANNEXIN PROTEINS AND  
METHODS FOR TREATING VASO-  
OCCLUSIVE SICKLE-CELL DISEASE

} EXAMINER:

} ART UNIT: 1653

} CONFIRMATION NO: 3876

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
Attn.: Office of Initial Patent Examination's  
Customer Service Center

**REQUEST FOR CORRECTION OF FILING RECEIPT**

Dear Sir:

The Applicant hereby requests that the filing receipt be corrected to reflect the correct assignee's address. A red marked copy of the Filing Receipt is enclosed for your ease of reference.

Respectfully submitted,

  
\_\_\_\_\_  
Darla G. Yoerg, #48,053  
Swanson & Bratschun, J.L.C.  
1745 Shea Center Drive, Suite 330  
Highlands Ranch, Colorado 80129  
(303) 268-0066 Telephone  
(303) 268-0065 Facsimile

cc: William Leschensky  
S:\CLIENT FOLDERS\SURROMED\113\FILING RECEIPT CORRECT.DOC


---

37 CFR 1.8

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Attn.: Office of Initial Patent Examination's Customer Service Center,  
on January 27, 2004.

Signature:   
Name: Denise S. Magee




## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/632,694	08/01/2003	1653	450	11757009 / SURRE113	3	15	2

25871  
 SWANSON & BRATSCHUN L.L.C.  
 1745 SHEA CENTER DRIVE  
 SUITE 330  
 HIGHLANDS RANCH, CO 80129



CONFIRMATION NO. 3876  
 UPDATED FILING RECEIPT



\*OC000000011757009\*

Date Mailed: 01/23/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Anthony Allison, Belmont, CA;

**Assignment For Published Patent Application**

SurroMed, Inc., Mountain View, CA;  
 Menlo Park,

**Domestic Priority data as claimed by applicant**

This application is a CIP of 10/080,370 02/21/2002  
 and claims benefit of 60/400,718 08/02/2002

**Foreign Applications**

If Required, Foreign Filing License Granted: 11/06/2003

Projected Publication Date: 05/06/2004

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease

Preliminary Class

435

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).